Pharmaceutical company Upsher-Smith Laboratories LLC revealed on Friday the launch of an exclusive agreement with a pharmaceutical partner to market and distribute a group of six ophthalmic and otic ANDA products, with combined annual sales of more than USD1.6bn (IQVIA, 12 months ending March 2018).
This partnership collaboration is part of its company-wide effort to grow its generics pipeline as well as expand its strategic relationships within the pharmaceutical industry.
The agreement allows Upsher-Smith to register the products with the US Food and Drug Administration (FDA) as well as market and distribute them under its own label in the US upon US FDA approval.
In conjunction, the partner company will develop and manufacture the products exclusively for Upsher-Smith.
Financial terms related to the deal have not been disclosed by the companies.
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling
Sandoz's Tyruko (natalizumab-sztn) gains FDA approval as first biosimilar for relapsing MS
Nephron Pharmaceutical names new chief procurement officer
Lupin Pharmaceuticals launches Tiotropium Bromide Inhalation Powder, 18mcg/capsule in US